Unaudited financial results for the quarter and nine months ended December 31, 2025
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech reported Q3 FY26 standalone revenue from operations of ₹11,424 lakhs, down about 22% YoY from ₹14,625 lakhs, primarily because the year-ago quarter included a one-time property sale of ₹3,602 lakhs from the Worli and Takawe assets. The core Bulk Drugs & Chemicals segment, however, grew roughly 10% YoY in Q3 and around 29% YoY for the nine months, showing strong underlying momentum. For 9M FY26, standalone revenue rose 10% to ₹34,038 lakhs and standalone PAT grew about 12% to ₹4,271 lakhs; on a consolidated basis, 9M revenue grew about 22.5% to ₹40,385 lakhs and consolidated PAT rose about 20% to ₹5,165 lakhs. The company booked an exceptional item of ₹210 lakhs (standalone) and ₹220 lakhs (consolidated) for incremental gratuity provisions arising from the new Labour Codes notified on November 21, 2025. The Environment Division was transferred on a slump sale basis to wholly-owned subsidiary Fermenta Environment Solutions on October 1, 2025, and auditor SRBC & Co LLP issued an unqualified limited review report.
Headline Q3 numbers look weak but are distorted by a one-off property sale in the base quarter; the underlying bulk drugs business is growing at nearly 30% over nine months, which is the real positive for shareholders. The Labour Codes charge is a one-time, non-cash adjustment and does not affect the core earnings trajectory.